AZD5122

AZD5122 is an investigational small molecule drug developed by AstraZeneca for the treatment of inflammatory diseases such as chronic obstructive pulmonary disease (COPD). It acts as a selective antagonist of the C-X-C chemokine receptor type 2 (CXCR2), a receptor involved in neutrophil recruitment and activation. By blocking CXCR2 signaling pathways—including cytokine-cytokine receptor interaction and chemokine signaling—AZD5122 aims to reduce inflammation associated with COPD and potentially other inflammatory conditions. The drug has been evaluated in phase 1 clinical trials to assess its pharmacokinetics following oral and intravenous administration in healthy male subjects[1][3][6].

Other names

(14C)AZD5122N-(2-(2,3-difluorobenzylthio)-6-(3,4-dihydroxybutan-2-ylamino)pyrimidin-4-yl)azetidine-1-sulfonamideN-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[[(1R,2R)-2,3-dihydroxy-1-methylpropyl]amino]-4-pyrimidinyl]-1-azetidinesulfonamide